iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: how to do it | Cancer Imaging | Full Text
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
RECIST 1.1 calculator - Radiology calculators
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
ABSTRACT INTRODUCTION BACKGROUND AND HISTORY
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
The Radiology Assistant : RECIST 1.1 - and more
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - ScienceDirect
Assessing Immunotherapy Response and Progression
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Cancers | Free Full-Text | Lights and Shadows in Immuno-Oncology Drug Development
The Radiology Assistant : RECIST 1.1 - and more
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
How to better understand iRECIST – a new wave in immunotherapeutic
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
